Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type a injection

BMC Urology

Volumn 12, Issue , 2012, Pages

  Gorgal, Tiago ^a,b   Charrua, Ana ^a,b,c,d   Silva, João F ^a,b,c   Avelino, Antánio ^b,c   Dinis, Paulo ^a,b,c   Cruz, Francisco ^a,b,c  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

apoptosis; Botulinum toxin; prostate

Indexed keywords

AVIDIN; BOTULINUM TOXIN A; CASPASE 3; PHENYLEPHRINE; PROTEIN BAX; PROTEIN BCL XL; SODIUM CHLORIDE; APOPTOSIS REGULATORY PROTEIN; BAX PROTEIN, RAT; BCL2L1 PROTEIN, RAT; PROTEIN BCL X;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DENSITY; CONTROLLED STUDY; DRUG MECHANISM; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OPTICAL DENSITY; PROSTATE HYPERTROPHY; RAT; ADRENERGIC SYSTEM; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BOTULINUM TOXINS, TYPE A; CASPASE 3; GENE EXPRESSION REGULATION; MALE; PROSTATE; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM;

EID: 84855257664     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-12-1     Document Type: Article

References (30)

1. Botulinum toxin for the lower urinary tract. Chuang YC, Kuo HC, Chancellor MB, BJU Int 2010 105 1046 1058 10.1111/j.1464-410X.2010.09317.x
2. Botox-induced prostatic involution. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA, Prostate 1998 37 44 50 10.1002/(SICI)1097-0045(19980915)37: 1<44::AID-PROS7>3.0.CO;2-8 9721068 (Pubitemid 28385184)
3. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. Chuang YC, Tu CH, Huang CC, Lin HJ, Chiang PH, Yoshimura N, Chancellor MB, BMC Urol 2006 18 6 12
4. Relief of botulinum toxin of voiding disfunction due to benign prostatic hyperplasia: results of randomized, placebo-controlled study. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A, Urology 2003 62 259 264 10.1016/S0090-4295(03)00477-1 12893330 (Pubitemid 36952073)
5. Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, Cruz F, Eur Urol 2008 53 153 159 10.1016/j.eururo.2007.08.050 17825981 (Pubitemid 350166733)
6. Mist 2: baseline PSA and total prostate volume predicts clinical response to intraprostatic injection of botulinum toxin for the management of LUTS. McVary K, Crawford ED, Donnell R, Drews K, Kaplan S, Kusek J, Roehrborn C, Bruskewitz R, J Urol 2010 183 Supp 1 690
7. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. Chuang YC, Huang CC, Kang HY, Chiang PH, Demiguel F, Yoshimura N, Chancellor MB, J Urol 2006 175 1158 1163 10.1016/S0022-5347(05) 00318-6 16469644 (Pubitemid 43200121)
8. Mechanisms of prostate atrophy after glandular botulinum neurotoxin type A injection: an experimental study in the rat. Silva J, Pinto R, Carvalho T, Coelho A, Avelino A, Dinis P, Cruz F, Eur Urol 2009 56 134 140 10.1016/j.eururo.2008.07.003 18649990
9. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB, Urology 2005 66 775 779 10.1016/j.urology.2005.04.029 16230137 (Pubitemid 41440823)
10. Growth of the rat prostate is facilitated by the autonomic nervous system. McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE, Biol Reprod 1994 51 99 107 10.1095/biolreprod51.1.99 7918880 (Pubitemid 24179226)
11. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. Gavrieli Y, Sherman Y, Ben-Sasson SA, J Cell Biol 1992 119 493 501 10.1083/jcb.119.3.493 1400587
12. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. Shariat SF, Ashfaq R, Roehrborn CG, Slawin KM, Lotan Y, Urology 2005 174 2046 2050 10.1097/01.ju.0000176459.79180.d1 (Pubitemid 41547021)
13. Serenoa repens treatment modifies Bax/Bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. Vela-Navarrete R, Escribano-Burgos M, Farré AL, García-Cardoso J, Manzarbeitia F, Carrasco C, Urology 2005 173 507 510 10.1097/01.ju.0000150533.94952.25
14. Apoptosis profiles in benign prostatic hyperplasia: close associations of cell kinetics with percent area density of histologic composition. Zhang X, Zhang Q, Zhang Z, Na Yanqun, Guo Y, Urology 2006 68 905 910 10.1016/j.urology. 2006.05.013 17070390 (Pubitemid 44633388)
15. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Boise LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nũez G, Thompson CB, Cell 1993 74 597 608 10.1016/0092-8674(93)90508-N 8358789 (Pubitemid 23259741)
16. Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. Charrua A, Avelino A, Cruz F, Handb Exp Pharmacol 2011 202 345 374
17. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. Pennefather JN, Lau WA, Mitchelson F, Ventura S, Auton Pharmacol 2000 20 193 206 10.1046/j.1365-2680.2000.00195.x (Pubitemid 34211031)
18. The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate. Dinis P, Charrua A, Avelino A, Nagy I, Quintas J, Ribau U, Cruz F, Eur Urol 2005 48 162 167 10.1016/j.eururo.2005. 01.009 15967267 (Pubitemid 40835615)
19. Requirement of innervation for maintenance of structural and functional integrity in the rat prostate. Wang JM, McKenna KE, McVary KT, Lee C, Biol Reprod 1991 44 1171 1176 10.1095/biolreprod44.6.1171 1873391
20. Rapid proliferation of prostatic epithelial cells in spontaneously hypertensive rats: a model of spontaneous hypertension and prostate hyperplasia. Matityahou A, Rosenzweig N, Golomb E, J Androl 2003 24 263 269 12634314
21. Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Anglin IE, Glassman DT, Kyprianou N, Prostate Cancer Prostatic Dis 2002 5 88 95 10.1038/sj.pcan.4500561 12496995 (Pubitemid 34777889)
22. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group, N Engl J Med 2003 349 2387 2398 10.1056/NEJMoa030656 14681504 (Pubitemid 37542987)
23. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. McVary KT, Rademaker A, Granville LL, Gann P, Urology 2005 174 1327 1333 10.1097/01.ju.0000173072.73702. 64 (Pubitemid 41318722)
24. Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperplasia. Ullrich PM, Lutgendorf SK, Kreder KJ, Urology 2007 70 487 491 10.1016/j.urology.2007.04.048 17905102 (Pubitemid 47464520)
25. Effects of botulinum toxin A on the contractile function of dog prostate. Lin AT, Yang AH, Chen KK, Eur Urol 2007 52 582 589 10.1016/j.eururo.2007.03.002 17386969 (Pubitemid 46963445)
26. Relief by Botulinum Toxin of Lower Urinary Tract Symptoms Owing to Benign Prostatic Hyperplasia: Early and Long-Term Results. Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G, Urology 2009 73 90 94 10.1016/j.urology.2008.08.475 18995889
27. Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Oliveira R, Silva C, Cruz F, Dinis P, BMC Urol 2009 9 9 10.1186/1471-2490-9-9 19682392
28. Prostate botulinum A toxin injection- an alternative treatment for benign prostatic obstruction in poor surgical candidates. Kuo HC, Urology 2005 65 670 674 10.1016/j.urology.2004.10.077 15833506 (Pubitemid 40522997)
29. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB, BJU Int 2006 98 1033 1037 10.1111/j.1464-410X.2006.06479.x 16956361 (Pubitemid 44536454)
30. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, Eur Urol 2010 57 123 131 10.1016/j.eururo.2009.09.035 19825505